Skip to content
Screener

Total Revenue at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$4.98B-9.5%
AptarGroup logo
AptarGroupATR
$982.87M+10.8%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$481M+47.7%
AVT
AvantorAVTR
$1.69B+0.5%
Cardinal Health, Inc. logo
Cardinal Health, Inc.CAH
$63.67B+5.8%
Dow logo
DowDOW
$12.09B+19.7%

Segments

By segment

See full
Proprietary Products$722.6M+16.6%
West Vantage$149.7M+2.0%

Other financials

Income statement

See full
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.63B+39.2%
Enterprise value$24.51B+40.2%
P/E43.6×+7.3×
P/S7.4×+1.4×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net sales$872.3$766.5$1,717.2$1,464.5
Cost of goods and services sold543.1492.61,091.6958.7
Gross profit329.2273.9625.6505.8
Research and development19.719.135.535.4
Selling, general and administrative expenses117.695.9217.1183.9
Other expense (income) (Note 14)12.85.216.825.8
Operating profit179.1153.7356.2260.7
Interest expense, net2.60.14.50.5

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's total revenue?
West Pharmaceutical Services (WST) reported total revenue of $872.3M in Q2 2026.
How has West Pharmaceutical Services's total revenue changed year-over-year?
West Pharmaceutical Services's total revenue increased by 13.8% year-over-year, from $766.5M to $872.3M.
What is the long-term trend for West Pharmaceutical Services's total revenue?
Over 4 years (2021 to 2025), West Pharmaceutical Services's total revenue has grown at a 2.1% compound annual growth rate (CAGR), from $2.83B to $3.07B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about West Pharmaceutical Services's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude